These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 25062770)

  • 1. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
    Xia C; Leon-Ferre R; Laux D; Deutsch J; Smith BJ; Frees M; Milhem M
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):691-7. PubMed ID: 25062770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
    Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
    Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis.
    Tawbi HA; Beumer JH; Tarhini AA; Moschos S; Buch SC; Egorin MJ; Lin Y; Christner S; Kirkwood JM
    Ann Oncol; 2013 Apr; 24(4):1112-9. PubMed ID: 23172636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study.
    Hummel TR; Wagner L; Ahern C; Fouladi M; Reid JM; McGovern RM; Ames MM; Gilbertson RJ; Horton T; Ingle AM; Weigel B; Blaney SM
    Pediatr Blood Cancer; 2013 Sep; 60(9):1452-7. PubMed ID: 23554030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.
    Hwu WJ; Panageas KS; Menell JH; Lamb LA; Aird S; Krown SE; Williams LJ; Chapman PB; Livingston PO; Wolchok JD; Houghton AN
    Cancer; 2006 Jun; 106(11):2445-51. PubMed ID: 16639739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma.
    McQuade JL; Posada LP; Lecagoonporn S; Cain S; Bassett RL; Patel SP; Hwu WJ; Hwu P; Davies MA; Bedikian AY; Amaria RN
    Melanoma Res; 2016 Dec; 26(6):604-608. PubMed ID: 27540836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
    Agarwala SS; Kirkwood JM
    Cancer; 2003 Jan; 97(1):121-7. PubMed ID: 12491513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion.
    Beasley GM; Speicher P; Augustine CK; Dolber PC; Peterson BL; Sharma K; Mosca PJ; Royal R; Ross M; Zager JS; Tyler DS
    Ann Surg Oncol; 2015 Jan; 22(1):287-94. PubMed ID: 25145500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
    Choy E; Flamand Y; Balasubramanian S; Butrynski JE; Harmon DC; George S; Cote GM; Wagner AJ; Morgan JA; Sirisawad M; Mani C; Hornicek FJ; Duan Z; Demetri GD
    Cancer; 2015 Apr; 121(8):1223-30. PubMed ID: 25536954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma.
    de Gast GC; Batchelor D; Kersten MJ; Vyth-Dreese FA; Sein J; van de Kasteele WF; Nooijen WJ; Nieweg OE; de Waal MA; Boogerd W
    Br J Cancer; 2003 Jan; 88(2):175-80. PubMed ID: 12610499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
    García M; del Muro XG; Tres A; Crespo C; Valladares M; López JJ; Rifà J; Pérez X; Filipovich E; Germà-Lluch JR
    Melanoma Res; 2006 Aug; 16(4):365-70. PubMed ID: 16845333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma.
    Ibrahim N; Buchbinder EI; Granter SR; Rodig SJ; Giobbie-Hurder A; Becerra C; Tsiaras A; Gjini E; Fisher DE; Hodi FS
    Cancer Med; 2016 Nov; 5(11):3041-3050. PubMed ID: 27748045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma.
    Larkin JM; Hughes SA; Beirne DA; Patel PM; Gibbens IM; Bate SC; Thomas K; Eisen TG; Gore ME
    Br J Cancer; 2007 Jan; 96(1):44-8. PubMed ID: 17146474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study.
    Schadendorf D; Hauschild A; Ugurel S; Thoelke A; Egberts F; Kreissig M; Linse R; Trefzer U; Vogt T; Tilgen W; Mohr P; Garbe C
    Ann Oncol; 2006 Oct; 17(10):1592-7. PubMed ID: 17005632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF.
    Lewis KD; Gibbs P; O'Day S; Richards J; Weber J; Anderson C; Zeng C; Baron A; Russ P; Gonzalez R
    Cancer Invest; 2005; 23(4):303-8. PubMed ID: 16100942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
    Gogas H; Polyzos A; Stavrinidis I; Frangia K; Tsoutsos D; Panagiotou P; Markopoulos C; Papadopoulos O; Pectasides D; Mantzourani M; Middleton M; Vaiopoulos G; Fountzilas G
    Ann Oncol; 2006 Dec; 17(12):1835-41. PubMed ID: 16980601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma.
    Kim KB; Hwu WJ; Papadopoulos NE; Bedikian AY; Camacho LH; Ng C; Hernandez IM; Frost AM; Jack MA; Hwu P
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):161-7. PubMed ID: 19002462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale).
    Guida M; Tommasi S; Strippoli S; Natalicchio MI; De Summa S; Pinto R; Cramarossa A; Albano A; Pisconti S; Aieta M; Ridolfi R; Azzariti A; Guida G; Lorusso V; Colucci G
    BMC Cancer; 2018 May; 18(1):552. PubMed ID: 29747595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases.
    Bael TE; Peterson BL; Gollob JA
    Melanoma Res; 2008 Apr; 18(2):147-51. PubMed ID: 18337652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.